Missouri is currently home to 1893 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
NCT06533761
Recruiting
This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) or r/r higher-risk myelodysplastic syndromes (HR-MDS). The study consists of 2 parts: * Part 1: Dose Escalation (DE) in both monotherapy and in combination.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Washington University in St Louis, St. Louis, Missouri
Conditions: AML, Adult, MDS
Register for Updates
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059
Recruiting
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Saint Louis, Missouri
Conditions: Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Register for Updates
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291
Recruiting
This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Healthcare Research Network - St. Louis ( Site 0040), Hazelwood, Missouri
Conditions: Hypercholesterolemia
Register for Updates
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
NCT06467084
Recruiting
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
07/09/2025
Locations: KalVista Investigative Site, Saint Louis, Missouri
Conditions: Hereditary Angioedema
Register for Updates
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
NCT06418711
Recruiting
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/09/2025
Locations: University of Missouri, Columbia, Missouri
Conditions: MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Register for Updates
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330
Recruiting
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
07/09/2025
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
Register for Updates
tAN for PTSD and OUD in Buprenorphine Therapy
NCT06130501
Recruiting
The goal of this research study supported by the HEAL Initiative (https://heal.nih.gov) is to investigate the effects transcutaneous auricular neurostimulation (tAN), as delivered through the Sparrow Ascent device, on helping people with co-occurring posttraumatic stress disorder (PTSD) and opioid use disorder (OUD) start and continue buprenorphine treatment. The main questions it aims to answer are: * Does the tAN help participants with OUD and PTSD remain in buprenorphine therapy for three mo... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/09/2025
Locations: Gibson Center for Behavioral Change, Cape Girardeau, Missouri
Conditions: Posttraumatic Stress Disorder, Opioid Use Disorder
Register for Updates
Examining Racial and Socioeconomic Differences in Chronic Low Back Pain
NCT05991440
Recruiting
The purpose of this research study is to gain a better understanding of how people's racial background and socioeconomic status (e.g., income, education, and employment) impact their experiences of chronic low back pain (cLBP).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/09/2025
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Chronic Pain
Register for Updates
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
NCT05611242
Recruiting
The primary objective is to establish the efficacy of intra-arterial (IA) mechanical thrombectomy (MT) with extracranial proximal carotid artery acute stenting versus non-stenting approaches in patients with acute ischemic stroke (AIS) from intracranial vessel occlusion (IVO) in the anterior circulation and have a proximal carotid occlusive disease (occlusion or severe stenosis).
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
07/09/2025
Locations: SSM Health DePaul Hospital, Saint Louis, Missouri
Conditions: Acute Ischemic Stroke
Register for Updates
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449
Recruiting
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
07/09/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Register for Updates
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT05422222
Recruiting
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Gender:
ALL
Ages:
Between 1 year and 11 years
Trial Updated:
07/09/2025
Locations: The Children's Mercy Hospital, Kansas City, Missouri
Conditions: Cystic Fibrosis
Register for Updates
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585
Recruiting
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/09/2025
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Register for Updates